biote Corp.
NASDAQ:BTMD · NASDAQ Global Market
+$0.03 today
Vol 0.20M · Avg 0.27M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $5.3M |
| Receivables | $7.4M |
| Inventory | $19.9M |
| Other Current | $3.8M |
| Total Current Assets | $36.4M |
| PP&E (Net) | $13.3M |
| Goodwill | $5.8M |
| Intangible Assets | $9.0M |
| Tax Assets | $24.5M |
| Other Non-current | $72.0K |
| Total Non-current Assets | $52.7M |
| Total Assets | $89.0M |
Analysis
Selected assets total $89.0M for Latest. The largest visible component is Tax Assets at $24.5M, about 27.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.1M -38.7% | $39.3M -55.8% | $89.0M +12.3% | $79.2M +196.0% | $26.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $7.7M -0.3% | $7.7M -5.8% | $8.2M +17.6% | $6.9M +32.8% | $5.2M | $533.8M | $399.4M | -$1.7B |
| Inventory | $19.1M +28.4% | $14.8M -14.2% | $17.3M +54.8% | $11.2M +16.3% | $9.6M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $10.0K -91.0% | $111.0K -64.0% | $308.0K | $0 -100.0% | $3.9M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $54.7M -19.8% | $68.1M -44.3% | $122.3M +20.9% | $101.2M +114.9% | $47.1M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $13.5M +31.7% | $10.2M +230.2% | $3.1M -13.0% | $3.6M +32.1% | $2.7M | $1.2B | $1.5B | $687.8M |
| Goodwill | $5.8M +0.0% | $5.8M | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $4.3M -54.5% | $9.4M +88.6% | $5.0M -2.0% | $5.1M +11.4% | $4.6M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $24.8M -13.7% | $28.7M +15.5% | $24.9M +1253.9% | $1.8M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $4.6M +6284.7% | $72.0K | $0 | $0 | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $52.9M -2.4% | $54.2M +64.6% | $33.0M +214.8% | $10.5M +44.5% | $7.2M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $107.6M -12.1% | $122.4M -21.2% | $155.3M +39.1% | $111.6M +105.5% | $54.3M | $13.3B | $11.9B | $10.6B |
| Account Payables | $6.8M +17.4% | $5.8M +39.9% | $4.2M +1.0% | $4.1M -5.4% | $4.3M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $6.3M +0.0% | $6.3M +0.0% | $6.3M +0.0% | $6.3M +25.0% | $5.0M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $17.0K -98.4% | $1.1M | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $3.0M +1.9% | $3.0M -1.4% | $3.0M +52.8% | $2.0M +15.2% | $1.7M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $22.5M -25.8% | $30.3M +399.7% | $6.1M +43.8% | $4.2M +90.7% | $2.2M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $45.0M -12.7% | $51.5M +131.9% | $22.2M +18.4% | $18.8M +8.4% | $17.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $100.8M -0.4% | $101.2M -5.1% | $106.6M -4.9% | $112.1M +250.7% | $32.0M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $1.1M -29.4% | $1.6M +17.5% | $1.3M +42.8% | $926.0K +15.5% | $802.0K | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $8.8M -86.9% | $67.4M +12.4% | $60.0M +65.7% | $36.2M +4415.5% | $802.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $113.0M -34.7% | $173.1M +2.0% | $169.6M +12.2% | $151.2M +359.5% | $32.9M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $158.0M -29.6% | $224.6M +17.1% | $191.8M +12.9% | $169.9M +238.5% | $50.2M | $14.7B | $3.7B | $9.6B |
| Common Stock | $4.0K +0.0% | $4.0K -33.3% | $6.0K +0.0% | $6.0K | $0 | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$49.5M +50.6% | -$100.3M -241.3% | -$29.4M +33.9% | -$44.5M -1167.5% | $4.2M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$29.0K +17.1% | -$35.0K -191.7% | -$12.0K -140.0% | -$5.0K +87.5% | -$40.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $8.1M +118.4% | $3.7M +152.1% | -$7.1M +48.3% | -$13.8M | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$50.4M +50.7% | -$102.2M -179.6% | -$36.5M +37.3% | -$58.3M -1512.7% | $4.1M | $9.1B | $7.7B | $3.3B |
| Total Debt | $109.9M -0.8% | $110.9M -3.5% | $114.9M -4.6% | $120.4M +222.5% | $37.3M | $724.2M | $410.6M | $399.4M |
| Net Debt | $85.8M +20.0% | $71.5M +176.5% | $25.9M -37.2% | $41.2M +289.7% | $10.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
The Joint Corp.
NASDAQ:JYNT
$136.57M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Scilex Holding Company
NASDAQ:SCLX
$72.18M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does BTMD have?
biote Corp. (BTMD) reported $24.12M in cash and equivalents in fiscal 2025.
How much debt does BTMD carry?
biote Corp. (BTMD) reported $109.92M of total debt, with net debt of $85.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.